A missense variant effect map for the human tumour suppressor protein CHK2

Marinella Gebbia,Daniel Zimmerman,Rosanna Jiang,Maria Nguyen,Jochen Weile,Roujia Li,Michelle Gavac,Nishka Kishore,Song Sun,Rick A Boonen,Jennifer N. Dines,Alexander Wahl,Jason Reuter,Britt Johnson,Douglas M Fowler,Haico van Attikum,Frederick P Roth

DOI: https://doi.org/10.1101/2024.02.13.579700

2024-02-15

Abstract:The tumour suppressor encodes the serine/threonine protein kinase CHK2 which, upon DNA damage, is important for pausing the cell cycle, initiating DNA repair and inducing apoptosis. CHK2 phosphorylation of the tumour suppressor BRCA1 is also important for mitotic spindle assembly and chromosomal stability. Consistent with its cell cycle checkpoint role, both germline and somatic variants in have been linked to breast and multiple other cancer types. Over 90% of clinical germline missense variants are classified as variants of uncertain significance, complicating diagnosis of CHK2-dependent cancer. We therefore sought to test the functional impact of all possible missense variants in CHK2. Using a scalable multiplexed assay based on the ability of human CHK2 to complement DNA sensitivity of a lacking its ortholog , we generated a systematic ‘missense variant effect map’ for missense variation. Map scores reflect known biochemical features of CHK2 and exhibit good performance in separating pathogenic from benign clinical missense variants. Thus, the missense variant effect map for CHK2 offers value in understanding both known and yet-to-be-observed CHK2 variants.

Genetics

What problem does this paper attempt to address?

The main goal of this paper is to address the complexity in diagnosing CHEK2-related cancers due to a large number of missense variants in the CHEK2 gene being classified as variants of uncertain significance (VUS). Specifically, over 90% of clinically discovered CHEK2 missense variants are categorized as VUS, posing a challenge for cancer risk assessment based on genetic information.

To tackle this challenge, the research team developed a large-scale screening method based on yeast complementation assays to systematically test the functional impact of all possible CHEK2 missense variants. By leveraging the ability of human CHK2 to compensate for the DNA damage sensitivity of Saccharomyces cerevisiae lacking its homologous gene RAD53, the researchers constructed a "missense variant effect map." This map not only covers known variants but also predicts the impact of potential new variants, thereby aiding in the improved clinical interpretation of these variants.

In summary, this study aims to improve the clinical interpretation of CHEK2 variants by generating a comprehensive functional effect map of missense variants, thereby enhancing the accuracy of cancer risk assessment based on genetic information.